Market atlas / NAD+ precursors / Niacin

Niacin (vitamin B3, NAD+ precursor)

traditional-to-validatedsmall-moleculenad-precursorlipid-lowering● nad-levels● ldl

Stage by geography

signalpreclinfirst-in-humanRCTapprovedreal-worldconsumerUSCHIL+3 stages

MarketsUS United States FDAUK United Kingdom MHRA / NICECN China NMPAIN India CDSCOJP Japan PMDACH Switzerland SwissmedicSG Singapore HSAIL Israel Ministry of HealthKR South Korea MFDS

What each market approved it for

Market	Stage	Since	Indication / class / form
US	consumer	not dated	not published
CH	signal	not dated	not published
IL	RCT	not dated	not published

Biomarker trends

no biomarker readings yet

Studies

The studies on Niacin, what they found, in whom and how strongly, are on its evidence page, each linked to its source.

What the trials measure

Registered primary outcomes this development's trials are powered on, commonest first (ClinicalTrials.gov). What is measured, across markets.

Registered primary endpoint	Markets measuring it
Blood Glucose Level	US
Blood Glucose Levels	US
Change in interoceptive awareness as measured by the Multidimensional Assessment of Interoceptive Awareness-2 from 4 weeks…	US
Change in Pain, Enjoyment, and General Activity (PEG) total score at 8 weeks post dose	US
Change in functional disability measured by the Oswestry Disability Index (ODI) from baseline to 8 weeks post-dose.	US
Composite End Point of CHD Death, Nonfatal MI, Ischemic Stroke, Hospitalization for Non-ST Segment Elevation Acute Coronary…	US
Effect on oxidative stress	IL

Connections

Trajectory

2000

MarketUS: approved-other (approved, marketed)

ANDA040378 · machine-extracted

2011

Relatedshares a mechanism with Nmn

NCT01237041 · machine-extracted

2011

ProfileNiacin (vitamin B3, NAD+ precursor)

NCT01237041 · machine-extracted

2011

MarketUS: rct (clinical trials (highest phase 2))

NCT01237041 · machine-extracted

2026

MarketUS: consumer (also sold as a US dietary supplement (vitamin B3))

DSLD:79943 · machine-extracted

2026

MarketCH: signal (clinical trials (highest phase ?))

NCT01683656 · machine-extracted

2026

MarketIL: rct (clinical trials (highest phase 3))

NCT01071525 · machine-extracted

Get into the weeds: raw observations + provenance

nia_us  2026-06-29  kind=geography_stage  verify=M
   Niacin (extended-release, e.g. Niaspan) FDA-approved for dyslipidaemia (US)
   source ANDA040378  https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=040378

nia_edge_nmn  2026-06-29  kind=edge  verify=M
   both NAD+ precursors
   source NCT01237041  https://clinicaltrials.gov/study/NCT01237041

nia_facets  2026-06-29  kind=facets  verify=M
   Niacin facets
   source NCT01237041  https://clinicaltrials.gov/study/NCT01237041

nia_us_trial  2026-06-29  kind=geography_stage  verify=M
   Niacin: US phase 2 trials [NCT01237041]
   source NCT01237041  https://clinicaltrials.gov/study/NCT01237041

nia_us_consumer  2026-06-29  kind=geography_stage  verify=M
   Niacin (vitamin B3) also sold as a US dietary supplement
   source DSLD:79943  https://dsld.od.nih.gov/label/79943

ctsearch__CH__dev_niacin  2026-07-10  kind=geography_stage  verify=M
   niacin: 1 registered trial(s) in CH, highest phase ? [NCT01683656]
   source NCT01683656  https://clinicaltrials.gov/study/NCT01683656

ctsearch__IL__dev_niacin  2026-07-10  kind=geography_stage  verify=M
   niacin: 3 registered trial(s) in IL, highest phase 3 [NCT01071525]
   source NCT01071525  https://clinicaltrials.gov/study/NCT01071525